The results of placebo-controlled randomized trial of effectiveness of haloinhalation treatment with application of individual inhaler Haloneb in 125 patients with allergic and vasomotor rhinitis demonstrated high efficacy of the method. A positive effect was achieved in 90.4% patients with allergic and 92.1% with vasomotor rhinitis. Efficacy of the method is explained by anti-edema, anti-allergic and anti-inflammatory effects of haloinhalation therapy.

Download full-text PDF

Source

Publication Analysis

Top Keywords

patients allergic
12
allergic vasomotor
8
vasomotor rhinitis
8
efficacy method
8
[haloinhalation therapy
4
therapy patients
4
vasomotor rhinitis]
4
rhinitis] placebo-controlled
4
placebo-controlled randomized
4
randomized trial
4

Similar Publications

A Retrospective Study of Pediatric Allergic Contact Dermatitis from 2017-2022.

Dermatol Ther (Heidelb)

January 2025

Burkhart Pediatric and Adolescent Dermatology, Cary, NC, USA.

Objectives: Allergic contact dermatitis occurs frequently in children. The proportion of children of color in the US is increasing, and racial and ethnic minority representation is important in pediatric allergic contact dermatitis research. The objectives of our study were to identify differences in age, sex, race and ethnicity among pediatric patch tests obtained from 2017 to 2022.

View Article and Find Full Text PDF

Background: The 2006 National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network (NIAID/FAAN) anaphylaxis criteria are widely used in clinical care and research. In 2020, the World Allergy Organization (WAO) published modified criteria that have not been uniformly adopted. Different criteria contribute to inconsistent care and research outcomes.

View Article and Find Full Text PDF

Major Depressive Disorder (MDD) is a widespread psychiatric condition impacting social and occupational functioning, making it a leading cause of disability. The diagnosis of MDD remains clinical, based on the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria, as biomarkers have not yet been validated for diagnostic purposes or as predictors of treatment response. Traditional treatment strategies often follow a one-size-fits-all approach obtaining suboptimal outcomes for many patients who fail to experience response or recovery.

View Article and Find Full Text PDF

An evaluation of Asthma control using the Asthma control test in patients at the University Hospital, Agadir, Morocco.

Niger Med J

January 2025

Health Sciences Research and Innovation Laboratory Medical School of Medicine & Pharmacy of Agadir, Ibn Zohr University, Agadir-Morocco.

Background: Asthma is a common chronic disease, and asthma control is the major therapeutic objective, thus ensuring a good health-related quality of life. This study aimed to evaluate the level of asthma control in a sample of asthmatic patients followed in allergology consultation during our training using the asthma control test (ACT) and its correlation with other parameters.

Methodology: This is a cross-sectional study of 66 asthmatic patients who were followed in pulmonology consultation at Agadir University Hospital after completing the asthma control test questionnaire over 6 months (June to December 2021).

View Article and Find Full Text PDF

The basophil activation test (BAT) has become a major cellular test for evaluating the allergenic activity of specific IgEs. The impact of the BAT is due to the ability of blood basophil granulocytes to present IgE on the high-affinity FcRI receptor and to mirror the mast cell response that elicits an acute allergic reaction. The BAT proved to be able to identify allergic patients at risk of reacting to a low dose of the allergen and/or developing life-threatening reactions and thus can significantly improve the current management of allergic patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!